Background

Multiple Sclerosis (MS) is a representative chronic inflammatory disease where the destruction of myelin in the central nervous system causes permanent impairment in nerve signal transmission. For decades, the medical community has identified the autoimmune response—where peripheral immune cells such as T cells and B cells breach the blood-brain barrier to indiscriminately attack nerve fibers in the brain and spinal cord—as the primary pathogenesis. Existing treatments have also focused on suppressing immune responses or depleting immune cells.

While current immunosuppressive therapies have succeeded in reducing the frequency of relapses in the early stages of the disease, they have failed to block progressive disability, where neurological function gradually declines. Many patients experience brain atrophy and cognitive decline even when immune inflammation is suppressed. Previous Genome-Wide Association Studies (GWAS) were primarily biased toward European populations and were limited to bulk tissue analysis, failing to fully isolate the differences in susceptibility across individual cell types that constitute actual brain tissue.

Key Findings

An international research team precisely integrated multi-ancestry GWAS data spanning diverse ancestral lineages with single-cell transcriptomic data from blood and brain tissues. By enhancing the resolution of disease risk signals by reflecting genetic diversity among populations, they traced back the cell clusters where risk variants are actually expressed at the single-cell transcriptomic level.

The results directly challenge the existing perception that immune cells are the sole starting point of the disease. In addition to peripheral immune cells, inhibitory neurons within the brain were clearly identified as a key target cell type where MS risk variants are concentrated. The analysis captured a pattern of significant enrichment of genetic variants in the gene regulatory regions of GABAergic inhibitory neurons, which coordinate the balance of excitation and inhibition in the nervous system.

This demonstrates that neurons are not merely passive victims of immune system attacks. It provides evidence that intrinsic molecular pathway abnormalities within inhibitory neurons trigger neural network dysfunction, which in turn creates a microenvironment vulnerable to immune attacks or directly accelerates neurodegeneration. The genetic vulnerability of the neurons themselves, which was hidden at the tissue level, has clearly surfaced thanks to single-cell resolution analysis.

Implications and Outlook

The research horizon for multiple sclerosis is expected to shift rapidly from a purely immunological domain to an interdisciplinary field integrating neurobiology. While disease-modifying therapies have focused solely on inducing immune tolerance thus far, the development of combination drugs targeting the metabolic stability and synaptic protection of damaged inhibitory neurons has emerged as a critical challenge.

The challenges are also clear. It is necessary to verify the specific molecular mechanisms by which genetic association signals influence the survival and circuit function of inhibitory neurons using human induced pluripotent stem cell (iPSC)-derived neuron models. It is time for follow-up research to determine the causal sequence: whether neuron-specific dysfunction is a primary cause that precedes the inflammatory response, or an auxiliary driver that leads to neurodegeneration in conjunction with inflammation amplification.